問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

石宇翔

Recruiting

List

26Cases

2025-02-01 - 2033-12-31

Phase III

Active
A phase 3, randomized, open-label, multicenter trial was conducted in patients with platinum-sensitive recurrent ovarian cancer to evaluate the efficacy and safety of sacituzumab tirumotecan (MK-2870) maintenance therapy with or without bevacizumab compared to standard care after second-line platinum-based doublet chemotherapy (TroFuse-022/ENGOT-ov84/GOG-3103).

  • Condition/Disease

    Part 1: (1) Adverse events (AEs) (2) Discontinuation of trial treatment due to AEs Part 2: (1) PFS: Time from randomization to the first recorded disease progression or death from any cause, whichever occurs first.

  • Test Drug

    Dexamethasone MK-2870 MVASI

Participate Sites
5Sites

Recruiting5Sites

2025-07-15 - 2030-12-31

Phase II

Active
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

  • Condition/Disease

    Malignant Neoplasm

  • Test Drug

    錠劑 錠劑 注射劑 錠劑 注射劑 錠劑

Participate Sites
3Sites

Recruiting3Sites

2025-03-01 - 2032-01-31

Phase III

Active
A phase 3, open-label, multicenter, randomized trial comparing trastuzumab deruxtecan plus bevacizumab versus bevacizumab alone as first-line maintenance therapy for HER2-positive ovarian cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13).

  • Condition/Disease

    Compare the efficacy of T-DXd plus bevacizumab (Group A) versus bevacizumab monotherapy (Group B) in the HER2 IHC 3+/2+ population, as assessed by BICR for progression-free survival (PFS).

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd、DS-8201a)

Participate Sites
7Sites

Recruiting7Sites

2025-10-01 - 2034-05-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

  • Condition/Disease

    Cervical Cancer

  • Test Drug

    注射劑 注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2030-05-18

Phase III

Active
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    注射用凍晶粉末 靜脈輸注液 輸注液 輸注液 濃縮粉劑 輸注液

Participate Sites
9Sites

Recruiting9Sites

2025-04-01 - 2032-12-31

Phase III

Active
A phase 3, randomized, open-label, multicenter trial was conducted in mismatched patients with intact endometrial cancer to compare the efficacy and safety of sacituzumab tirumotecan (Sac-TMT, MK-2870) plus pembrolizumab versus pembrolizumab alone as first-line maintenance therapy (TroFuse-033/GOG-3119/ENGOT-en29).

  • Condition/Disease

    Progression-free survival (PFS): Time from randomization to the first recorded disease progression or death from any cause, whichever occurs first. Overall survival (OS): Time from randomization to death from any cause.

  • Test Drug

    Pembrolizumab (MK-3475) Sacituzumab Tirumotecan (MK-2870)

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-07-30 - 2031-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2028-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2030-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB